Joshua Cohen (left) and Justin Klee (Amylyx)
September 2, 2020 05:07 PM EDTUpdated September 3, 07:15 AM
R&D

Amy­lyx spot­lights a PhII suc­cess in slow­ing ALS pro­gres­sion. And they’re tak­ing it to the FDA

Max Gelman

Senior Editor

Just a cou­ple months af­ter pulling in a $30 mil­lion Se­ries B round, Amy­lyx is mak­ing an­oth­er splash with what it hopes are promis­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Pfiz­er CEO says op­por­tu­ni­ties with Trump ‘clear­ly out­weigh’ the risks for phar­ma

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times